Sep
14
2021
--

AgBiome lands $116M for safer crop protection technology

AgBiome, developing products from microbial communities, brought in a $116 million Series D round as the company prepares to pad its pipeline with new products.

The company, based in Research Triangle Park, N.C., was co-founded in 2012 by a group including co-CEOs Scott Uknes and Eric Ward, who have known each other for over 30 years. They created the Genesis discovery platform to capture diverse microbes for agricultural applications, like crop protection, and screen the strains for the best assays that would work for insect, disease and nematode control.

“The microbial world is immense,” said Uknes, who explained that there is estimated to be a trillion microbes, but only 1% have been discovered. The microbes already discovered are used by humans for things like pharmaceuticals, food and agriculture. AgBiome built its database in Genesis to house over 100,000 microbes and every genome in every microbe was sequenced into hundreds of strains.

The company randomly selects strains and looks for the best family of strains with a certain activity, like preventing fungus on strawberries, and creates the product.

AgBiome co-CEOs Scott Uknes and Eric Ward. Image Credits: AgBiome

Its first fungicide product, Howler, was launched last year and works on more than 300 crop-disease combinations. The company saw 10x sales growth in 2020, Uknes told TechCrunch. As part of farmers’ integrated pest program, they often spray fungicide applications 12 times per year in order to yield fruits and vegetables.

Due to its safer formula, Howler can be used as the last spray in the program, and its differentiator is a shorter re-entry period — farmers can spray in the morning and be able to go back out in the field in the afternoon. It also has a shorter pre-harvest time of four hours after application. Other fungicides on the market today require seven days before re-entry and pre-harvest, Uknes explained.

AgBiome aims to add a second fungicide product, Theia, in early 2022, while a third, Esendo was submitted for Environmental Protection Agency registration. Uknes expects to have 11 products, also expanding into insecticides and herbicides, by 2025.

The oversubscribed Series D round was co-led by Blue Horizon and Novalis LifeSciences and included multiple new and existing investors. The latest investment gives AgBiome over $200 million in total funding to date. The company’s last funding round was a $65 million Series C raised in 2018.

While competitors in synthetic biology often sell their companies to someone who can manufacture their products, Uknes said AgBiome decided to manufacture and commercialize the products itself, something he is proud of his team for being able to do.

“We want to feed the world responsibly, and these products have the ability to substitute for synthetic chemicals and provide growers a way to protect their crops, especially as consumers want natural, sustainable tools,” he added.

The company has grown to over 100 employees and will use the new funding to accelerate production of its two new products, building out its manufacturing capacity in North America and expanding its footprint internationally. Uknes anticipates growing its employee headcount to 300 in the next five years.

AgBiome anticipates rolling up some smaller companies that have a product in production to expand its pipeline in addition to its organic growth. As a result, Uknes said he was particular about the kind of investment partners that would work best toward that goal.

Przemek Obloj, managing partner at Blue Horizon, was introduced to the company by existing investors. His firm has an impact fund focused on the future of food and began investing in alternative proteins in 2016 before expanding that to delivery systems in agriculture technology, he said.

Obloj said AgBiome is operating in a $60 billion market where the problems include products that put toxic chemicals into the ground that end up in water systems. While the solution would be to not do that, not doing that would mean produce doesn’t grow as well, he added.

The change in technology in agriculture is enabling Uknes and Ward to do something that wasn’t possible 10 years ago because there was not enough compute or storage power to discover and sequence microbes.

“We don’t want to pollute the Earth, but we have to find a way to feed 9 billion people by 2050,” Obloj said. “With AgBiome, there is an alternative way to protect crops than by polluting the Earth or having health risks.”

May
07
2020
--

VC’s largest funds make big bets on vertical B2B marketplaces

During the waning days of the first dot-com boom, some of the biggest names in venture capital invested in marketplaces and directories whose sole function was to consolidate information and foster transparency in industries that had remained opaque for decades.

The thesis was that thousands of small businesses were making specialized products consumed by larger businesses in huge industries, but the reach of smaller players was limited by their dependence on a sales structure built on conferences and personal interactions.

Companies making pharmaceuticals, chemicals, construction materials and medical supplies represented trillions in sales, but those huge aggregate numbers hide how fragmented these supply chains are — and how difficult it is for buyers to see the breadth of sellers available.

Now, similar to the way business models popularized by Kozmo.com and Webvan in decades past have since been reincarnated as Postmates and DoorDash, the B2B directory and marketplace rises from the investment graveyard.

The first sign of life for the directory model came with the success of GoodRX back in 2011. The company proved that when information about pricing in a previously opaque industry becomes available, it can unleash a torrent of new demand.

May
07
2020
--

Dtex, a specialist in insider threat cybersecurity, raises $17.5M

A lot of enterprise cybersecurity efforts focus on malicious hackers that work on behalf of larger organizations, be they criminal groups or state actors — and for good reason, since the majority of incidents these days come from phishing and other malicious techniques that originate outside the enterprise itself.

But there has also been a persistent, and now growing, focus also on “insider threats” — that is, breaches that start from within organizations themselves. And today a startup that specialises in this area is announcing a round of growth funding to expand its reach.

Dtex, which uses machine learning to monitor network activity within the perimeter and around all endpoints to detect unusual patterns or behaviour around passwords, data movement and other network activities, is today announcing that it has raised $17.5 million in funding.

The round is being led by new investor Northgate Capital with Norwest Venture Partners and Four Rivers Group, both previous investors, also participating. Prior to this, the San Jose-based startup had raised $57.5 million, according to data from PitchBook, while CrunchBase puts the total raised at $40 million.

CEO Bahman Mahbod said the startup is not disclosing valuation except to say that it’s “very excited” about it.

For some context, the company works with hundreds of large enterprises, primarily in the financial, critical infrastructure, government and defence sectors. The plan is to now extend further into newer verticals where it’s started to see more activity more recently: pharmaceuticals, life sciences and manufacturing. Dtex says that over the past 12 months, 80% of its top customers have been increasing their level of engagement with the startup.

Dtex’s focus on “insider” threats sounds slightly sinister at first. Is the implication here that people are more dishonest and nefarious these days and thus need to be policed and monitored much more closely for wrongdoing? The answer is no. There are no more dishonest people today than there ever have been, but there are a lot more opportunities to make mistakes that result in security breaches.

The working world has been on a long-term trend of becoming increasingly digitised in all of its interactions, and bringing on a lot more devices onto those networks. Across both “knowledge” and front-line workers, we now have a vastly larger number of devices being used to help workers do their jobs or just keep in touch with the company as they work, with many of them being brought by the workers themselves rather than being provisioned by the companies. There has also been a huge increase in cloud services,

And in the realm of “knowledge” workers, we’re seeing a lot more remote or peripatetic working, where people don’t have fixed desks and often work outside the office altogether — something that has skyrocketed in recent times with stay-at-home orders put in place to mitigate the spread of COVID-19 cases.

All of this translates into a much wider threat “horizon” within organizations themselves, before even considering the sophistication of external malicious hackers.

And the current state of business has exacerbated that. Mahbod tells us that Dtex is currently seeing spikes in unusual activity from the rise in home workers, who sometimes circumvent VPNs and other security controls, thus committing policy violations; as well as more problems arising from the fact that home networks have been compromised and that is leaving work networks, accessed from home, more vulnerable. These started, he said, with COVID-19 phishing attacks but have progressed to undetected malware from drive-by downloads.

And, inevitably, he added that there has been a rise in intentional data theft and accidental loss arising in cases where organizations have had to lay people off or run a round of furloughs, but might still result from negligence rather than intentional actions.

There are a number of other cybersecurity companies that provide ways to detect insider threats — they include CloudKnox and Obsidian Security, along with a number of larger and established vendors. But Mabhod says that Dtex “is the only company with ‘next-generation’ capabilities that are cloud-first, AI/ML baked-in, and enterprise scalable to millions of users and devices, which it sells as DMAP+.

“Effectively, Next-Gen Insider Threat solutions must replace legacy Insider Threat point solutions which were borne out of the UAM, DLP and UEBA spaces,” he said.

Those providing legacy approaches of that kind include Forcepoint with its SureView product and Proofpoint with its ObserveIT product. Interestingly, CyberX, which is currently in the process of getting acquired by Microsoft (according to reports and also our sources), also includes insider threats in its services.

This is one reason why investors have been interested.

“Dtex has built a highly scalable platform that utilizes a cloud-first, lightweight endpoint architecture, offering clients a number of use cases including insider threat prevention and business operations intelligence,” said Thorsten Claus, partner, Northgate Capital, in a statement. Northgate has a long list of enterprise startups in its portfolio that represent potential customers but also a track record of experience in assessing the problem at hand and building products to address it. “With Dtex, we have found a fast-growing, long-term, investible operation that is not just a band-aid collection of tools, which would be short-lived and replaced.”

Apr
28
2020
--

SkyCell raises $62M for smart containers and analytics to transport pharmaceuticals

While human travel has become severely restricted in recent months, the movement of goods has remained a constant priority — and in some cases, has become even more urgent. Today, a startup out of Switzerland that builds hardware and operates a logistics network designed to transport one item in particular — pharmaceuticals — is announcing a significant round to fuel its growth.

SkyCell — a designer of “smart containers” powered by software to maintain constant conditions for drugs that need to be kept at strict temperatures, humidity levels, and levels of vibration, which are in turn used to transport pharmaceuticals around the globe on behalf of drug companies — is today announcing. that it has raised $62 million in growth funding.

This latest round is being led by healthcare investor MVM Partners, with participation also from family offices, a Swiss insurance company that declined to be named, as well as previous investors the Swiss Entrepreneurs Fund (managed by Credit Suisse and UBS), and the BCGE Bank’s growth fund.

The company was founded in 2012 Switzerland when Richard Ettl and Nico Ros were tasked to design a storage facility for one of the big Swiss pharma giants. The exec charged with overseeing the project brainstormed that the work they were putting in could potentially be applied to transportation containers, and thus SkyCell was born.

Today, Ettl (who is the CEO, while Ros is the CTO), said in an interview that the company now works with eight of the world’s biggest pharmaceutical companies and has been in validation trials with a further seven. These use SkyCell’s network of some 22,000 air freight pallets to move their products around the world.

The new capital will be used to expand that reach further, specifically in the U.S. and Asia, and to double its fleet to become the biggest pharmaceutical transportation company globally. With 30 of the 50 biggest-selling drugs in the world being temperature sensitive (and some generics for one of the biggest-selling, the arthritis medication Humira, now also coming out), this makes for a huge opportunity.

And unsurprisingly, several of SkyCell’s customers are working on COVID-19 medications, Ettl said, either to help ease symptoms or potentially to vaccinate or eradicate the virus, and so it’s standing at the ready to play a role in getting drugs to where they need to be.

“We are well positioned in case there is a vaccine developed. Out of the six pharma companies developing these right now, four of them are our customers, so there is a high likelihood we would transport something,” Ettl said.

For now, he said SkyCell has been involved in helping to transport “supportive” medications related to the outbreak, such as flu shots to make sure people are not falling ill with other viral infections at the same time.

SkyCell is not disclosing its valuation but we understand that it’s in the many hundreds of millions of dollars. The company had raised some $36 million in equity and debt before this, bringing the total outside funding now to $98 million.

In a market that’s estimated to be worth some $2.8 billion annually and growing at a rate of between 15% and 20% each year, there are a number of freight businesses that focus on the transportation of pharmaceuticals. They include not only freight companies but airlines themselves, which often buy in containers from third parties. (And for some more context, one of its competitors, Envirotainer, was acquired for over $1 billion in 2918; while another, CSafe, has raised significantly more funding.)

But there was virtually no innovation in the market, and most pharmaceutical companies factored in failure rates of between 4% and 12% depending on where the drugs were headed.

One key differentiator with SkyCell has been its containers, which are able to withstand temperatures as high as 60 degrees Celsius or as low as negative 10 degrees Celsius, and have tracking on them to better monitor their movements from A to B.

These came to the market at a time when incumbents were only able to (and some still are only able to) guarantee insulation for temperatures as high as 40 degrees, which was not as pressing an issue in the past as it is today, in part because of rising temperatures around the globe, and in part because of the growing sophistication of pharmaceuticals.

“We’ve found that the number of days where [one has to consider] temperature extremes has been going up,” Ettl said. “Last year, we had 30 days where it was warmer than 40 degrees Celsius across our network of countries.”

On top of the containers themselves, SkyCell has built a software platform that taps into the kind of big data analytics that are now part and parcel of how modern companies in the logistics industry work today, in order to optimise movement and best routing for packages.

The conditions it considers include not only the obvious ones around temperature, humidity and vibration, but distance and time of travel, as well as overall carbon emissions. SkyCell claims that its failure rate comes out at less than 0.1%, with CO2 emissions reduced by almost half on a typical shipment.

Together, the hardware and software are covered by some 100 patents, the company says.

Jun
13
2019
--

IBM, KPMG, Merck, Walmart team up for drug supply chain blockchain pilot

IBM announced its latest blockchain initiative today. This one is in partnership with KPMG, Merk and Walmart to build a drug supply chain blockchain pilot.

These four companies are coming together to help come up with a solution to track certain drugs as they move through a supply chain. IBM is acting as the technology partner, KPMG brings a deep understanding of the compliance issues, Merk is of course a drug company and Walmart would be a drug distributor through its pharmacies and care clinics.

The idea is to give each drug package a unique identifier that you can track through the supply chain from manufacturer to pharmacy to consumer. Seems simple enough, but the fact is that companies are loathe to share any data with one another. The blockchain would provide an irrefutable record of each transaction as the drug moved along the supply chain, giving authorities and participants an easy audit trail.

The pilot is part of a set of programs being conducted by various stakeholders at the request of the FDA. The end goal is to find solutions to help comply with the U.S. Drug Supply Chain Security Act. According to the FDA Pilot Program website, “FDA’s DSCSA Pilot Project Program is intended to assist drug supply chain stakeholders, including FDA, in developing the electronic, interoperable system that will identify and trace certain prescription drugs as they are distributed within the United States.”

IBM hopes that this blockchain pilot will show it can build a blockchain platform or network on top of which other companies can build applications. “The network in this case, would have the ability to exchange information about these pharmaceutical shipments in a way that ensures privacy, but that is validated,” Mark Treshock, global blockchain solutions leader for healthcare and life sciences at IBM told TechCrunch.

He believes that this would help bring companies on board that might be concerned about the privacy of their information in a public system like this, something that drug companies in particular worry about. Trying to build an interoperable system is a challenge, but Treshock sees the blockchain as a tidy solution for this issue.

Some people have said that blockchain is a solution looking for a problem, but IBM has been looking at it more practically, with several real-world projects in production, including one to track leafy greens from field to store with Walmart and a shipping supply chain with Maersk to track shipping containers as they move throughout the world.

Treshock believes the Walmart food blockchain is particularly applicable here and could be used as a template of sorts to build the drug supply blockchain. “It’s very similar, tracking food to tracking drugs, and we are leveraging or adopting the assets that we built for food trust to this problem. We’re taking that platform and adapting it to track pharmaceuticals,” he explained.

Powered by WordPress | Theme: Aeros 2.0 by TheBuckmaker.com